TLP
ALDX icon

Tri Locum Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Tri Locum Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-73,067
Closed -$613K – 62
2023
Q2 		$613K Buy
+73,067
New +$720K 0.23% 43
2022
Q2 		– Sell
-1,447,445
Closed -$6.43M – 52
2022
Q1 		$6.43M Buy
+1,447,445
New +$5.77M 2.51% 21
2021
Q3 		– Sell
-818,025
Closed -$9.27M – 29
2021
Q2 		$9.27M Buy
+818,025
New +$9.84M 3.03% 10

Other funds holding ALDX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Tri Locum Partners's ALDX Position: Q3 2023 in Review

Tri Locum Partners sold out of Aldeyra Therapeutics (ALDX) in Q3 2023, closing a stake of 73,067 shares — an estimated $613K sold.

Tri Locum Partners first reported a position in ALDX in Q2 2021 and held it in 3 quarters. The position peaked at $9.27M in Q2 2021. 120 funds tracked by Wall St. Rank hold ALDX as of Q3 2023.

  • Tri Locum Partners reported no remaining Aldeyra Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Tri Locum Partners sold 73,067 Aldeyra Therapeutics shares in Q3 2023, an estimated $613K.
  • Tri Locum Partners first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 3 quarters.
  • Tri Locum Partners's Aldeyra Therapeutics position peaked at $9.27M in Q2 2021.
  • 120 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2023.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.